Bioventus (BVS) Operating Margin (2020 - 2026)

Bioventus (BVS) has reported Operating Margin for 7 consecutive years, with 12.48% the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Margin rose 4.0% year-over-year to 12.48%; the trailing twelve-month figure through Jun 2026 stood at 10.02% (up 389.0% YoY), and the FY2025 full-year result was 9.5%, up 1215.0% from the prior year.
• Operating Margin advanced to 12.48% in Q2 2026 per BVS's latest filing, from 6.37% in the prior quarter.
• Across five years, Operating Margin topped out at 12.48% in Q2 2026 and bottomed at 98.58% in Q4 2022.
• Historically, Operating Margin has averaged 8.6% across 5 years, with a median of 3.22% in 2024.
• The sharpest annual moves came in 2022 and 2023: Operating Margin tumbled 9762 bps in 2022, then jumped 10058 bps in 2023.
• Over 5 years, Operating Margin stood at 12.43% in 2022, then surged by 107 bps to 0.86% in 2023, then surged by 483 bps to 5.01% in 2024, then soared by 146 bps to 12.34% in 2025, then climbed by 1 bps to 12.48% in 2026.
• According to Business Quant data, Operating Margin over the past three periods registered 12.48%, 6.37%, and 12.34% for Q2 2026, Q1 2026, and Q4 2025 respectively.